Fast Five Quiz: Hidradenitis Suppurativa Management

William D. James, MD


November 05, 2019

According to European Dermatology Forum guidelines, systemic treatment with the biologic agents adalimumab or infliximab is reserved for patients with treatment-resistant, moderate to severe hidradenitis suppurativa (moderate Hurley II or Hurley III stage). These agents should be used only after lack of response to other agents such as clindamycin, rifampin, doxycycline, and acitretin. Etanercept should not be used in patients with moderate to severe hidradenitis suppurativa that is unresponsive to conventional systemic therapy.

Pain management should be offered as needed, and general measures to improve quality of life, such as smoking cessation, weight loss, and help with bandaging lesions, should be offered to all patients with hidradenitis suppurativa.

Learn more about treatment guidelines for chronic hidradenitis suppurativa.

Follow Medscape on Facebook, Twitter, Instagram, and YouTube


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.